No Cover Image

Journal article 1393 views

Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus

Jeffrey Stephens Orcid Logo, T Bodvarsdottir, K Wareham, Sarah Prior Orcid Logo, R Bracken, G Lowe, A Rumley, G Dunseath, Steve Luzio, C Deacon, J Holst, Steve Bain, Richard Bracken Orcid Logo, Gareth Dunseath Orcid Logo, Steve Luzio Orcid Logo

Diabetes Research and Clinical Practice, Volume: 94, Issue: 2, Pages: 199 - 206

Swansea University Authors: Jeffrey Stephens Orcid Logo, Sarah Prior Orcid Logo, Richard Bracken Orcid Logo, Gareth Dunseath Orcid Logo, Steve Luzio Orcid Logo

Full text not available from this repository: check for access using links below.

DOI (Published version): 10.1016/j.diabres.2011.07.014

Abstract

To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin.A randomized clinical trial was performed recruiting 27 subjects (HbA1c between...

Full description

Published in: Diabetes Research and Clinical Practice
Published: 2011
Online Access: http://www.sciencedirect.com/science/article/pii/S0168822711003640
URI: https://cronfa.swan.ac.uk/Record/cronfa10733
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin.A randomized clinical trial was performed recruiting 27 subjects (HbA1c between 7.5 and 10.5%) free from cardiovascular and renal disease. Glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), total antioxidant status, F2-isoprostane, interleukin-6 and cell adhesion molecules were measured during an oral glucose load at baseline and after eight weeks of treatment. The areas under the curve were analysed at 45, 60 and 120 min (AUC45, AUC60, AUC120).Significant improvements in glucose were observed with repaglinide (HBA1c: −1.5%, fasting glucose: −2.8 mmol/L, 2-h glucose: −3.7 mmol/L, AUC120: −18.9%) and glibenclamide (−1.0%, −2.2 mmol/L, −2.5 mmol/L, −17.5%). Repaglinide was also associated with an increase in the AUC60 and AUC120 for insulin (+56%, +61%) and C-peptide (+41%, +36%). GLP-1, GIP, IL-6, ICAM-1 and E-selectin levels did not change in either group. No association was observed between GLP-1, GIP-1 and plasma markers of oxidative stress.Repaglinide is associated with improved postprandial glycaemic control via insulin and C-peptide release. We observed no direct effects of glibenclamide or repaglinide on plasma levels of GLP-1 or GIP. We observed no associations of GLP-1 and GIP with plasma markers of oxidative stress.
Keywords: Glibenclamide; Repaglinide; GLP-1; GIP; Insulin; Oxidative stress; Diabetes
College: Faculty of Medicine, Health and Life Sciences
Issue: 2
Start Page: 199
End Page: 206